Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 10, 2011

Genentech Pays Array $28M Up Front for ChK-1 Anticancer Drug Deal

  • Genentech is paying Array BioPharma $28 million up front as part of a cancer drug deal focused on developing both firms’ small molecule checkpoint kinase 1 (ChK-1) programs. Genentech’s own Phase I-stage compound GDC-0425 (RG7602), and Array’s IND-ready candidate ARRY-575, will be included in the collaboration.

    Genentech and Array have been working together since 2004 on specific oncology programs and progressed an AKT inhibitor GDC-0068 into clinical development in 2010. Under terms of the new ChK-1 agreement Genentech will be responsible for all clinical development and commercialization activities, and Array could receive clinical and commercial milestone payments of up to $685 million, plus double-digit sales royalties.  

    Array is focused on the development of targeted small molecule drugs against cancer and inflammatory disease candidates. The firm’s clinical pipeline is headed by the Her2/EGFR targeting candidate ARRY-534, which is in Phase II trials against solid tumors, and a KSP-targeting drug ARRY-520, also in Phase II trials against acute myeloid leukemia and multiple myeloma. Array’s clinical pipeline also includes anticancer candidates targeting Her2 (ARRY-380) , and P38/Tie-2 (ARRY-614), which are in Phase I development against breast cancer and myelodysplastic syndrome, respectively.   

    In July Aslan Pharmaceuticals negotiated global rights to develop ARRY-543 through proof-of-concept trials. Under terms of the agreement the firm will initially develop the drug for gastric cancer.

    Array’s deal with Aslan followed just a month after it confirmed having to cut 20% of its workforce as part of a restructuring plan it hopes will reduce cash burn by $20 million during fiscal 2012. At the time the firm said it intends to push on with development of ARRY-520, ARRY-614, and MEK162, a MEK inhibitor anticancer candidate that is being developed in collaboration with Novartis.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »